Research on pharmaceutical research and development in the bioinformatics era

生物信息学时代的药物研发研究

基本信息

批准号：
15530257
负责人：
HARA Takuji
金额：
$ 2.18万
依托单位：
Kobe University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2003
资助国家：
日本
起止时间：
2003 至 2005
项目状态：
已结题

项目摘要

This study aims to investigate the influence of bioinformatics on the process and management of pharmaceutical research and development. The methodologies are document investigation and semi-structured interviews with researchers, managers and specialists working abroad and in Japan. The study also includes investigation about the history and the current situation of bioinformatics in the UK, France, Sweden and Japan, focusing on its relationship to the pharmaceutical R&D. In addition, the investigator researches the change of R&D process, organization and strategy in Japanese pharmaceutical companies.This study concludes that bioinformatics has changed the process of pharmaceutical R&D into the one accompanied with the molecular biological approach. This promotes the technological rationality of pharmaceutical R&D, but it does not necessarily promote the economic rationality. This is partly because bioinformatics does not cover the entire process of pharmaceutical R&D, partly because … More human creativity and organizational capabilities are necessary to evaluate the data, and partly because of the cost of bioinformatics use, the characteristics of market, and the situation of competition. All of these factors moderate the economic impact of bioinformatics on the pharmaceutical R&D. However, it is certain that bioinformatics significantly changes the R&D process of pharmaceuticals by adding to the aspect of the molecular biological mechanism (including the social shaping of the mechanism), and by facilitating the division of labor among different types of organization, such as universities, pharmaceutical companies, start-ups, and so on. This study also examines the "bridging problem" between the academic world and the business world, related to the division of labor in the area of pharmaceutical R&D.The results of this study are published as two English journal papers, four Japanese journal papers, one presentation at an international academic conference, one presentation at a national academic conference (to be held in September 2006) and a book review. Less

本研究旨在了解生物信息学对药物研发过程和管理的影响，方法是对国内外研究人员、管理人员和专家进行文献调查和半结构化访谈，还包括对历史的调查。以及英国、法国、瑞典和日本的生物信息学现状，重点关注其与药品研发的关系。此外，研究者还研究了日本制药公司的研发流程、组织和策略的变化。本研究得出的结论是：生物信息学将药物研发过程转变为与分子生物学方法相伴的过程，这促进了药物研发的技术合理性，但并不一定促进了经济合理性，部分原因是生物信息学并没有涵盖制药的整个过程。研发，部分是因为评估数据需要人类的创造力和组织能力，部分是因为生物信息学的使用成本、市场特征和竞争状况所有这些因素都会减轻经济影响。然而，可以肯定的是，生物信息学通过增加分子生物学机制（包括机制的社会塑造）方面以及促进不同部门之间的分工，显着改变了药物的研发过程。这项研究还探讨了学术界和商业界之间与制药领域分工相关的“桥梁问题”。 R&D.本研究成果发表为两篇英文期刊论文、四篇日文期刊论文、一篇国际学术会议报告、一篇全国学术会议报告（将于2006年9月举行）和一篇书评。